In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
about
Plasmid-determined AmpC-type beta-lactamases.Three decades of beta-lactamase inhibitorsChemistry and biosynthesis of clavulanic acid and other clavamsPenicillin-binding proteins and bacterial resistance to beta-lactamsA novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumoniabeta-Lactamase epidemiology and the utility of established and novel beta-lactamase inhibitors.Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa.blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United StatesCurrent antimicrobial therapy of anaerobic infections.Rapid identification of metallo- and serine beta-lactamasesEmergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.Susceptibilities of 540 anaerobic gram-negative bacilli to amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanate, temafloxacin, and clindamycin.Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infectionsPharmacokinetic studies and renal dehydropeptidase stability of the new beta-lactamase inhibitor BRL 42715 in animalsCurrent challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.New antibacterial agents: patent applications published in 2011.Kinetic study of interaction between BRL 42715, beta-lactamases, and D-alanyl-D-alanine peptidases.In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms.Discovery and development of new antibiotics: the problem of antibiotic resistancePartial characterization of Nocardia farcinica beta-lactamases.Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia.Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications."Nonantibiotics"--their relevance in research and potential place in future antimicrobial chemotherapy.A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.Kinetic and physical studies of beta-lactamase inhibition by a novel penem, BRL 42715.
P2860
Q24535748-20841A76-A35F-4CEE-8F52-0A989A138195Q24646623-B1008FE7-EEF4-41E7-BDCD-E5606872D554Q28247865-3AA8FEFC-E300-49BC-A108-86D9008D8522Q28257231-E5C19CBC-4306-42B4-9D87-5425BE96710FQ33977370-B02FFCAA-D871-4CB9-B1FF-522CA674A68AQ34074695-5B8EC6AB-A53C-4251-8AAD-8B274AE4261FQ34510522-65340DB6-CF7D-4321-95E9-3B66754D38B8Q35005911-242397AE-2D61-4178-B5E3-925F0E681DDDQ35212734-7C38F637-6D45-4441-92CD-023DF3E114D9Q35820302-CEE34705-E820-42EE-A6D8-8754D77A9A71Q35820623-DEBC6465-89EC-4BCC-83B3-06D61B5E6E7AQ35836795-372ED20A-7A63-49A0-87A8-A3757E8D734AQ35884909-F82B5F89-8C50-4916-B9FF-D5F9F4032831Q36754774-0D1C9BA9-8591-4051-A44E-528E8DDA9D08Q37731521-53B5F261-F78B-442E-BEE3-CA42E3CFA7ADQ38172657-E7C70BCC-1843-4E32-87B3-12B647BB9B19Q39778973-7F2026C2-7244-484C-8581-C627A73DD017Q39792561-1B8F0587-E21B-40BD-B96B-7C34FA43E746Q39865095-EBB5063A-8DE5-4088-A205-7EC475DA012BQ39866586-AD7118B7-FD0F-4860-8033-DF1CDE00B445Q40285545-894F67E0-19E8-401E-8353-6C44BD1272B5Q40286399-CEB10DA5-F7D4-41A5-ABA0-642DF8D8FDE1Q40923467-1AF91E70-35E3-4DE4-8008-0238F584158CQ41126137-7D97A507-F838-4AE2-A7CF-56C627627293Q41189315-1034A9DE-2F07-4A99-A4A6-863EBC55A2FBQ42831248-01CE2830-C0C6-4AA0-A76F-C0EA000DCA4A
P2860
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
@ast
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
@en
type
label
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
@ast
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
@en
prefLabel
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
@ast
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
@en
P2093
P2860
P356
P1476
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
@en
P2093
P2860
P304
P356
10.1128/AAC.33.9.1580
P407
P577
1989-09-01T00:00:00Z